Compare WBX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | BMEA |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 98.6M |
| IPO Year | N/A | 2021 |
| Metric | WBX | BMEA |
|---|---|---|
| Price | $3.01 | $1.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $9.00 | $8.71 |
| AVG Volume (30 Days) | 34.2K | ★ 1.2M |
| Earning Date | 02-26-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,593,453.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.87 |
| 52 Week High | $12.30 | $4.59 |
| Indicator | WBX | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 54.08 |
| Support Level | $2.84 | $1.31 |
| Resistance Level | $3.13 | $1.66 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 85.54 | 47.13 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.